Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial
作者
Leslie M. Randall,Michael W. Sill,Robert A. Burger,Bradley J. Monk,Barbara Buening,Joel I. Sorosky